ALPN - One Target Hit. Going Again.

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.

SHORT INTEREST
22.54K 08/15/19

P/E Current
-1.86

P/E Ratio (with extraordinary items)
-1.92

Average Recommendation: BUY

Average Target Price: 13.50